I-MAB ( (IMAB) ) just unveiled an update.
I-Mab announced its strategic focus on three clinically active programs, with Givastomig leading the pipeline. The company completed the divestiture of its China operations in 2024 and is executing a disciplined capital approach to accelerate growth. The announcement highlights the ongoing clinical development of Givastomig, Uliledlimab, and Ragistomig, with significant milestones expected in 2025 and 2026. These developments are aimed at enhancing I-Mab’s positioning in the precision immuno-oncology sector, potentially impacting stakeholders by advancing treatment options for gastric cancer and other malignancies.
More about I-MAB
I-Mab is a biopharmaceutical company focused on the development of innovative biologics in the field of immuno-oncology. The company is engaged in advancing a pipeline of drug candidates, including bispecific antibodies and monoclonal antibodies, targeting various cancers with a focus on precision immuno-oncology therapeutics.
YTD Price Performance: 4.29%
Average Trading Volume: 418,035
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $73.16M
Learn more about IMAB stock on TipRanks’ Stock Analysis page.